Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Employers expect healthcare costs to rise by a median of 9% in 2026, according to a survey by the Business Group on Health. Pharmacy expenses are a key driver.

Even with venture capital fundraising slowing down, Hatteras Venture Partners was able to close two new funds for investments in seed- and early-stage companies. We also have a recap of recent ...

Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new ...